ARA-290, also known as Cibinetide, is an investigational synthetic peptide derived from erythropoietin (EPO). Unlike traditional EPO, ARA-290 was engineered to provide tissue-protective and anti-inflammatory effects without significantly stimulating red blood cell production. It has gained attention in regenerative and neurology research for its potential role in nerve repair, inflammation modulation, and neuropathic pain support.
🔬 How ARA-290 Works
ARA-290 selectively activates the Innate Repair Receptor (IRR), a receptor involved in:
* Tissue repair and regeneration
* Anti-inflammatory signaling
* Nerve protection pathways
* Cellular stress-response modulation
* Microvascular support
Unlike erythropoietin, ARA-290 is designed to avoid strong erythropoietic (red blood cell–stimulating) effects, which may reduce some cardiovascular risks associated with EPO therapies.
🧬 Research suggests ARA-290 may help support:
* Small nerve fiber regeneration
* Neuropathic pain pathways
* Reduction of inflammatory cytokines
* Tissue protection after injury
* Microvascular and endothelial health
Some studies also suggest it may influence TRPV1 pain-signaling pathways directly. ([ScienceDirect][3])
🌸 Common Research & Wellness Interest
ARA-290 is commonly explored in research involving:
* Neuropathic pain support
* Small fiber neuropathy
* Diabetic neuropathy research
* Nerve-repair and regeneration studies
* Inflammation modulation
* Recovery and regenerative medicine
* Tissue-protection pathways
Clinical research in sarcoidosis-associated neuropathy and diabetic neuropathy has shown promising findings involving symptom improvement and nerve-fiber regeneration markers.
⏱ Onset & Duration
* Effects vary depending on the condition being studied
* Nerve-support and inflammatory effects are generally evaluated over weeks rather than immediately
* Some studies used repeated dosing over several weeks to evaluate outcomes
💉 Common Forms
* Subcutaneous injection
* Lyophilized peptide research formulations
⚠️ Possible Side Effects
Reported side effects in clinical and investigational settings are generally mild but may include:
* Injection-site irritation
* Headache
* Mild nausea
* Temporary fatigue
* Gastrointestinal discomfort in some individuals
Human long-term safety data remains limited because ARA-290 is still investigational.
🚫 Who Should Use Caution
Individuals should consult a healthcare professional before considering investigational peptide therapies, especially those with:
* Autoimmune conditions
* Cardiovascular disease
* Pregnancy or breastfeeding concerns
* Chronic neurological disorders
* Complex metabolic conditions
📌 Storage
* Store lyophilized peptide in a cool, dry place
* Refrigerate after reconstitution
* Protect from heat and direct sunlight
* Follow sterile handling procedures carefully
🧬 Research & Clinical Interest
ARA-290 continues to be explored in research involving:
* Peripheral neuropathy
* Diabetic nerve damage
* Sarcoidosis-associated small fiber neuropathy
* Inflammatory and ischemic tissue injury
* Neuroprotection and regenerative medicine
* Healthy-aging and tissue-repair pathways
⚠️ Important Note
ARA-290 (Cibinetide) remains investigational and does not currently have broad FDA approval for neuropathy, regenerative medicine, or wellness applications. Most current use occurs in research settings or experimental protocols. ([Mind Body Neurology][5])
Disclaimer: For research and educational purposes only. This product does not diagnose, treat, cure, or prevent any disease. Always consult with your doctor or healthcare professional before starting any investigational peptide or wellness-related program.
SKU: ARA290
